Clinical trials: Diffuse Large Cell
Diffuse Large B-Cell Lymphoma
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
This is a prospective, randomized, controlled, multicenter, phase II clinical trial to evaluate the efficacy and safety of R-CMOP versus R-CHOP in the initial treatment of low-risk and medium-risk diffuse large B-cell lymphoma…
- Trial name
- NCT06760039
- Testing
- R-CMOP Regimen, R-CHOP Regimen
- Where
- 10 sites in China
- Volunteers
- 112 people
- Sponsor
- Sun Yat-sen University
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T
This phase II trial tests the effectiveness of odronextamab given before chimeric antigen receptor T (CAR-T) cell therapy (bridging therapy) in patients with large B-cell lymphomas that have come back after a period of…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma
- Trial name
- NCT06784726
- Testing
- Odronextamab, Biospecimen Collection, Bone Marrow Aspiration
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Washington
Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse
An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
The purpose of this study is to assess overall response rate [ORR, including complete response (CR) and partial response (PR)], of daratumumab in participants with non-Hodgkin's lymphoma [a cancer of the lymph nodes (or…
- Conditions
- Lymphoma, Mantle-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- NCT02413489
- Testing
- Daratumumab
- Where
- 35 sites in United States, Australia and 5 more
- Volunteers
- 36 people
- Sponsor
- Janssen Research & Development, LLC
Relapsed or Refractory Aggressive B-Cell Non-Hodgkins Lymphoma
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) followed by glofitamab monotherapy treatment regimen (Cohort…
- Trial name
- NCT06806033
- Testing
- Obinutuzumab, Glofitamab, Gemcitabine
- Where
- 53 sites in United States, Australia and 5 more
- Volunteers
- 130 people
- Sponsor
- Hoffmann-La Roche
Pirtobrutinib, Immunochemotherapy
Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
This is an open-label, prospective, single-arm, multicenter study designed to evaluate the efficacy and safety of MTX plus pirtobrutinib combined with routinely-used clinical chemoimmunotherapy regimens in patients with DLBCL and…
- Conditions
- Pirtobrutinib, Immunochemotherapy, DLBCL - Diffuse Large B Cell Lymphoma, CNS Involvement of Systemic Lymphoma
- Trial name
- NCT07812493
- Testing
- pirtobrutinib+MTX+immunolchemotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Pengpeng Xu
Lymphoma
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003143
- Testing
- Amifostine, DHAP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)
SC291-101 is a Phase 1 study to evaluate SC291 safety and tolerability, anti-tumor activity, cellular kinetics, immunogenicity, and exploratory biomarkers.
- Trial name
- NCT05878184
- Testing
- SC291
- Where
- 10 sites in United States, Australia
- Volunteers
- 16 people
- Sponsor
- Sana Biotechnology
Lymphoma, Large B-Cell, Diffuse
R-ACVBP and DA-EPOCH-R in Patients With Non-GCB DLBCL
This is a randomized, open-label, multi-center, phase 3 study evaluating the efficacy of R-ACVBP and DA-EPOCH-R in patients with newly diagnosed non-germinal b-cell-like diffuse large B-cell lymphoma
- Trial name
- NCT03018626
- Testing
- Rituximab, Etoposide, Doxorubicin
- Where
- China
- Volunteers
- 402 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Diffuse Large B Cell Lymphoma
Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
This phase II study will evaluate whether a reduction in radiation dose and field size will maintain a high rate of local control while minimizing the risk of acute and late toxicity .
- Trial name
- DLBCL (NCT03681535)
- Testing
- Radiation Therapy
- Where
- 12 sites in United States, Czechia and 4 more
- Volunteers
- 243 people
- Sponsor
- Duke University
Diffuse Large B Cell Lymphoma
Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
The trial will enroll 194 previously untreated DLBCL patients over 20 months, with the objective to send to the local investigator an extensive molecular tumor characterization by D38 in at least 80% of enrolled patients.
- Trial name
- RT3 (NCT03104478)
- Testing
- Biological samples collection
- Where
- 15 sites in France
- Volunteers
- 219 people
- Sponsor
- The Lymphoma Academic Research Organisation
CD20 Positive, Chronic Lymphocytic Leukemia
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant
This phase I trial studies the best dose and how well bendamustine works with standard chemotherapy (fludarabine, rituximab) in treating participants with lymphoid cancers undergoing stem cell transplant.
- Conditions
- CD20 Positive, Chronic Lymphocytic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT00880815
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-Thymocyte Globulin, Bendamustine
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Large B-cell Diffuse Lymphoma of Testis
Safety and Feasibility Study of Combination of State of Art Chemoimmunotherapy, Intensive Central Nervous System Prophylaxis and Scrotal Irradiation to Treat Primary Diffuse Large B-cell Lymphoma of Testis
This trial is a phase II non-comparative study aimed to determine the feasibility and toxicity of the R-CHOP regimen in combination with intrathecal liposomal cytarabine and systemic intermediate-dose methotrexate followed by…
- Trial name
- IELSG30 (NCT00945724)
- Testing
- Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate
- Where
- 22 sites in Italy, Switzerland
- Volunteers
- 54 people
- Sponsor
- International Extranodal Lymphoma Study Group (IELSG)
Lung Cancer, Lymphoma
AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: AMG 706 may stop the growth of cancer cells by blocking blood flow to the cancer or by blocking some of the enzymes needed for cell growth.
- Conditions
- Lung Cancer, Lymphoma, Lymphoproliferative Disorder, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00324597
- Testing
- gemcitabine hydrochloride, motesanib diphosphate, pharmacological study
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
This I/II trial studies the side effects and best dose of lenalidomide when given together with nivolumab and to see how well they work in treating patients with non-Hodgkin or Hodgkin lymphoma that has come back and does not…
- Conditions
- Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma
- Trial name
- NCT03015896
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- David Bond, MD
Lymphoma, Small Intestine Cancer
Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer
Phase I trial to study the effectiveness of rebeccamycin analog and cisplatin with or without filgrastim in treating patients who have advanced cancer.
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004189
- Testing
- filgrastim, becatecarin, cisplatin
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
DHL, THL
Study on the Treatment of Double/Triple-hit DLBCL With Chidamide and Lisaftoclax in Combination With Pola-R-CHP
This is an open-label, multicenter clinical study for patients aged 65 and above with double/triple-hit diffuse large B-cell lymphoma who are not suitable for transplantation.
- Conditions
- DHL, THL, DLBCL - Diffuse Large B Cell Lymphoma
- Trial name
- NCT07552324
- Testing
- CL-Pola-R-CHP
- Volunteers
- 28 people
- Sponsor
- Ruijin Hospital
Lymphoma
A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse Large B Cell Lymphoma
The researchers are doing this study to find out whether the combination of epcoritamab with tafasitamab and lenalidomide is a safe and effective treatment for relapsed or refractory DLBCL.
- Trial name
- ECLAT (NCT07030699)
- Testing
- Epcoritamab, Lenalidomide, Tafasitamab
- Sponsor
- Memorial Sloan Kettering Cancer Center
Diffuse Large B Cell Lymphoma
Characterization and Clinical Impact of the Gut Microbiota in Lymphoma
The study is a prospective observational single-center cohort study which compare the gut microbiome of newly diagnosed Diffuse Large B-cell Lymphoma patients with the gut microbiome of healthy controls.
- Trial name
- NCT06161896
- Testing
- Stool samples
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Lars Møller Pedersen
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Collecting and Storing Blood Samples From Patients With Cancer
RATIONALE: Collecting and storing samples of blood from patients with cancer to test in the laboratory may help the study of cancer in the future.
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00900120
- Sponsor
- University of Medicine and Dentistry of New Jersey
DLBCL - Diffuse Large B Cell Lymphoma, Pirtobrutinib
Pirtobrutinib+Pola-R-CHP for Newly Diagnosed Non-GCB DLBCL
This is a single-arm, open-label, multicenter clinical study evaluating the efficacy and safety of pirtobrutinib combined with Pola-R-CHP in previously untreated Non-GCB DLBCL.
- Trial name
- NCT07744724
- Testing
- Pirtobrutinib+Pola-R-CHP
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Changzhou No.2 People's Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.